Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a near-total absence of ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

Eli Lilly's tirzepatide has been shown to significantly ... over the weekend and simultaneously published in the New England Journal of Medicine – also showed that treatment with the dual ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

according to a study in The New England Journal of Medicine. Congenital generalized lipodystrophy (CGL), which affects only a few thousand people worldwide, results in severe metabolic disease, ...

Tirzepatide, the active ingredient in ... according to research published Jan. 29 in The New England Journal of Medicine. Congenital generalized lipodystrophy — a disorder that significantly ...

In the face of abrupt weight loss, one of the most common consequences is hair loss, even after bariatric surgery. Losing ...

After 52 weeks, around 52% of patients on a 5 mg dose of tirzepatide had an absence ... The data has also been published in the New England Journal of Medicine. More than 50% of patients in ...

Predictably, Big Pharma has come up with an alternative – tirzepatide (brand name ... a study on semaglutide published in The New England Journal of Medicine in 2021, he says, 'The challenge ...

Predictably, Big Pharma has come up with an alternative – tirzepatide (brand name ... a study on semaglutide published in The New England Journal of Medicine in 2021, he says, 'The challenge ...